Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the breast
• * Metastatic disease
• Meets 1 of the following criteria:
• * Chemotherapy-unresponsive disease defined as 1 of the following:
• * Less than a partial response to 2 consecutive chemotherapy regimens that included an anthracycline and a taxane in combination or succession
• * Progression of disease during or within 3 months of completion of a taxane, anthracycline, or platinol-based regimen
• * Histologically confirmed tumor involvement on bone marrow biopsy
• Measurable or evaluable disease\* defined as the following:
• * Bidimensionally reproducible measurable mass by physical examination, ultrasonography, radiography, CT scan, or MRI
• * Evaluable lesions apparent on clinical exam, x-ray, CT scan, or MRI which do not fit the criteria for measurability (e.g., ill-defined post-surgical masses or masses assessable in 1 dimension only)
• * Elevation of biological markers (e.g., CA 27.29) is considered evaluable disease NOTE: \*Bone lesions or pleural or peritoneal effusion alone are not considered measurable or evaluable disease
• Appropriate candidate for allogeneic stem cell transplantation
• No active CNS metastases
• Available HLA-identical sibling donor
• * 6/6 antigen match
• * Donor CD34 cells at least 2 times 10\^6/kg recipient weight
• Hormone receptor status:
• * Estrogen receptor negative or positive
• * Estrogen receptor positive tumors must demonstrate progression on at least 1 hormonal manipulation
• PATIENT CHARACTERISTICS:
• Age
• 18 to 60
• Sex
• Female
• Menopausal status
• Not specified
• Performance status
• Karnofsky 70-100% OR
• ECOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• WBC at least 1,500/mm\^3
• Platelet count at least 30,000/mm\^3
• Hepatic
• Bilirubin less than 3 times normal\*
• AST and ALT less than 3 times normal\* NOTE: \*Unless abnormality due to malignancy
• Renal
• Creatinine no greater than 1.6 mg/dL
• Cardiovascular
• LVEF greater than 40% by echocardiography or MUGA
• No myocardial infarction within the past 6 months
• Pulmonary
• DLCO greater than 40% of predicted
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No serious localized or systemic infection
• No hypersensitivity to E. coli-derived products
• No history of non-breast malignant disease within the past 5 years except completely excised nonmelanoma skin cancer or carcinoma in situ of the cervix
• No chronic inflammatory disorder requiring concurrent glucocorticosteroids or other immunosuppressive medication
• No psychological condition or social situation that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• See Disease Characteristics
• Endocrine therapy
• No concurrent glucocorticoids
• Radiotherapy
• No prior radiotherapy to an indicator lesion unless the lesion shows evidence of progression after discontinuation of the therapy
• Surgery
• Not specified
• Other
• No concurrent immunosuppressive medication